Additional Paid in Capital of Corbus Pharmaceuticals Holdings, Inc. from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Corbus Pharmaceuticals Holdings, Inc. quarterly Additional Paid in Capital in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • Corbus Pharmaceuticals Holdings, Inc. Additional Paid in Capital for the quarter ending 31 Dec 2025 was $702,984,000, a 14% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Corbus Pharmaceuticals Holdings, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $702,984,000 +$83,699,000 +14% 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $627,024,000 +$9,371,000 +1.5% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $622,562,000 +$43,052,000 +7.4% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $620,999,000 +$80,123,090 +15% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $619,285,000 +$189,505,000 +44% 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $617,653,000 +$188,671,802 +44% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $579,510,000 +$151,356,748 +35% 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $540,875,910 +$114,523,432 +27% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $429,780,000 +$4,583,641 +1.1% 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $428,981,198 +$5,639,129 +1.3% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $428,153,252 +$6,156,708 +1.5% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $426,352,478 +$5,869,022 +1.4% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $425,196,359 +$6,292,539 +1.5% 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $423,342,069 +$6,243,808 +1.5% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $421,996,544 +$7,747,515 +1.9% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $420,483,456 +$8,791,694 +2.1% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $418,903,820 +$69,545,442 +20% 31 Dec 2021 10-K 07 Mar 2023 2022 FY
Q3 2021 $417,098,261 +$92,399,299 +28% 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $414,249,029 +$105,257,134 +34% 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $411,691,762 +$166,526,763 +68% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $349,358,378 +$150,383,322 +76% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $324,698,962 +$128,821,559 +66% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $308,991,895 +$116,172,164 +60% 30 Jun 2020 10-Q/A 31 Aug 2020 2020 Q2
Q1 2020 $245,164,999 +$55,265,445 +29% 31 Mar 2020 10-Q 11 May 2020 2020 Q1
Q4 2019 $198,975,056 +$50,086,421 +34% 31 Dec 2019 10-K 15 Mar 2021 2020 FY
Q3 2019 $195,877,403 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $192,819,731 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $189,899,554 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $148,888,635 31 Dec 2018 10-K 16 Mar 2020 2019 FY
Q3 2015 $21,949,288 +$11,769,208 +116% 30 Sep 2015 10-Q 10 Nov 2015 2015 Q3
Q2 2015 $15,291,395 30 Jun 2015 10-Q 13 Aug 2015 2015 Q2
Q1 2015 $10,651,766 31 Mar 2015 10-Q 13 May 2015 2015 Q1
Q4 2014 $10,287,214 +$10,184,518 31 Dec 2014 10-Q 10 Nov 2015 2015 Q3
Q3 2014 $10,180,080 30 Sep 2014 10-Q 13 Nov 2014 2014 Q3
Q4 2013 $102,696* 31 Dec 2013 10-K 10 Feb 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.